We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -0.14% | 35.55 | 35.60 | 36.05 | 36.50 | 35.55 | 36.45 | 350,596 | 16:15:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.32 | 106.9M |
Date | Subject | Author | Discuss |
---|---|---|---|
06/2/2024 11:07 | Morning Not a holder as yet, but looks good timing to enter FUM when it settles down - bang on to go ito profitablilty this Year as they FC at the last interims. Cyber - 20% is not a constant in the results ... still very early days only launched in UK end of April 23. Cash looks more than ample to take this through and so many market to attack.. I will be buying once it settles | givmesunshine | |
06/2/2024 10:44 | From LSE board. Investment bank Liberum, in a note to clients, said: "Aside from a little timing difference that has already reversed out, Futura is progressing in line with expectations and today’s trading update is a timely reminder of how much progress the company has made and how little credit it has been given for this progress." At 8.39 am, the shares were up 10.1p at 37.8p. Liberum reckons there is still a lot further for the stock to go with its 131p price target. | 2 solaris | |
06/2/2024 10:28 | This looks very positive for the company, they're clearly gaining traction and shouldn't be in any danger of running out of cash now. And they get good margins.My concern is that they have only been making small millions in revenues, after achieving 20% of the market in the UK and Belgium etc. Surely the market must be bigger than that?? | cyberbub | |
06/2/2024 10:20 | Thanks genierub for your post on HE1 which alerted me to this share. I top sliced there and put the profits here as I think this is going to be massive and over a decent period of time. It will be worldwide in the near future and the share price will act accordingly. In my opinion of course. | 2 solaris | |
06/2/2024 10:18 | The £65M of negative reserves B/Fwd at the half year stage is rather killing my ardour at the moment to invest as there will not be any dividend soon although the product is clearly gaining traction. Anyone know how the up front payment works eg is it deducted from revenues or is it a one off they keep the lot etc. Anyone know the potential size of the USA mkt? Appologies I do not wish to dampen the reaction it would just help. | seagreen | |
06/2/2024 10:10 | Tiger this was for UK and Beligum only. If we can kill it in 2 small markets, imagine when this product goes out to whole of EU and America. Unbelieveable upside here and not even ramping. | genierub | |
06/2/2024 09:59 | Not even all the eu but only U.K. and Belgium. Soon they will add Spain, Italy etc…as the rns. What about the Middle East, they have a lot of money and plenty of time to shake the mattress few times a day lol. So a lot news to be released even before the full update by April. Anyone found it hard to buy around 8:30? | comek | |
06/2/2024 09:58 | Agree about the sales and future market comments, the greatest opportunity success brings is the opportunity for more success! | k8 rhm | |
06/2/2024 09:56 | Not even all the eu but only U.K. and Belgium l. Soon they will add Spain Italy etc…What about the Middle East, they have a lot of money and plenty of time to shake the mattress few times a day lol. So a lot news to be released even before the full update by April. Anyone found hard to buy around 8:30? | comek | |
06/2/2024 09:45 | A lot of people getting excited don't even realise the sales they just smashed are for EU market. The USA sales are yet to start and when they do, this will be a 10X. Life changing stock if you do the deep dive. GLA | eyeofthetiger | |
06/2/2024 09:19 | Loved reading the RNS releases and game changing product. This has a lot of legs in it and the sales are fantastic. Well done FUM team. Can see this at 100p+ | wrecktangle | |
06/2/2024 08:50 | Auction at 40p. This is going off | genierub | |
06/2/2024 08:44 | For me this is now derisked to an important degree (still need US launch) with a revised broker target of £1.31 out today Dyor and no advice etc | takeiteasy | |
06/2/2024 08:40 | Go back to my post a month or so ago. This now has the license to go back to 100p+ | eyeofthetiger | |
06/2/2024 08:34 | Sales would be £3.6m and have beaten £3.4m if the £0.5m had not been delayed to Jan. If US gets going 2024 could be a transformational year for FUM and share price | oxford43 | |
06/2/2024 08:18 | So you are now going to say you are long - how much time you have been wasting here lols :) | takeiteasy | |
06/2/2024 08:13 | Trinity were forecasting £3.4m sales for 2023 Wellness Investors: Beware The Placebo Trap What’s the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo | mdi | |
06/2/2024 07:44 | Launches in multiple key countries expected by April. 2 good announcements. Shares disappointing at 28p. Confirmation of US launch is what I want to see. | broomrigg | |
06/2/2024 07:30 | Proven demand for Eroxon - early data shows >20% market share in the UK and Belgium Generation of first meaningful revenues and strong cash position | j777j | |
06/2/2024 07:22 | Trading update just outThe Board expects to report its first meaningful revenues generated from product sales for the year to 31 December of circa £3.1m followed by a strong January, post period, as additional orders in excess of £0.5m were delivered in early January rather than December as originally planned. The Company delivered a gross margin of approximately 58% and has ended the period with a cash position of £7.7m, providing a solid foundation for Futura as it enters 2024. | wheeze | |
05/2/2024 05:23 | "unqualified professional medics"? | glavey | |
04/2/2024 08:10 | Part 2 of the Eroxon PR fight back is now underway. Part 1 was to get You Tube to remove the misleading videos which I think is well underway. Part 2 is a lot more interesting. Just over the last month more than 20 supportive videos have appeared in a number of different languages from right across the globe with different and catchy themes. This all is lining up I suspect for the wider global availability of the product. I get the feeling at last that some professionals are getting back control over the sales process. Yes, we are not going to stop the Amazon scammers but getting control over You Tube health advice is a very good start. Finally, I can say well done to the firm and please keep the momentum up. Even if we cannot see sales information at the moment, seeing proper PR on the ground is a really decent start - alongside all the GB news TV advertising etc... dyor etc | takeiteasy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions